Literature DB >> 8659621

High levels of dopamine D2 receptor occupancy with low-dose haloperidol treatment: a PET study.

S Kapur1, G Remington, C Jones, A Wilson, J DaSilva, S Houle, R Zipursky.   

Abstract

OBJECTIVE: The purpose of this study was to determine the dopamine D2 receptor occupancy induced by low-dose haloperidol treatment in a prospective trial.
METHOD: Seven patients with schizophrenia were treated with 2 mg/day of haloperidol for 2 weeks, and D2 receptor occupancy was measured by [11C]raclopride and positron emission tomography.
RESULTS: The patients showed high levels of D2 occupancy (53%-74%); five of them showed substantial clinical improvement, and none showed important side effects.
CONCLUSIONS: The findings demonstrate that low doses of haloperidol induce D2 receptor occupancies that are in the putative therapeutic range. In combination with recent empirical trials, these findings should encourage clinicians to initiate treatment of psychotic episodes with low (2-4 mg haloperidol equivalent) doses of typical neuroleptics, particularly for first-episode patients.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8659621     DOI: 10.1176/ajp.153.7.948

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  44 in total

Review 1.  Novel antipsychotics: issues and controversies. Typicality of atypical antipsychotics.

Authors:  E Stip
Journal:  J Psychiatry Neurosci       Date:  2000-03       Impact factor: 6.186

Review 2.  Improving outcome in schizophrenia: the case for early intervention.

Authors:  A K Malla; R M Norman; L P Voruganti
Journal:  CMAJ       Date:  1999-03-23       Impact factor: 8.262

Review 3.  Dosing and switching strategies for paliperidone palmitate: based on population pharmacokinetic modelling and clinical trial data.

Authors:  Mahesh N Samtani; Srihari Gopal; Cristiana Gassmann-Mayer; Larry Alphs; Joseph M Palumbo
Journal:  CNS Drugs       Date:  2011-10-01       Impact factor: 5.749

4.  Relationship between dose, drug levels, and D2 receptor occupancy for the atypical antipsychotics risperidone and paliperidone.

Authors:  E C Muly; J R Votaw; J Ritchie; L L Howell
Journal:  J Pharmacol Exp Ther       Date:  2012-01-03       Impact factor: 4.030

Review 5.  The development, past achievements, and future directions of brain PET.

Authors:  Terry Jones; Eugenii A Rabiner
Journal:  J Cereb Blood Flow Metab       Date:  2012-03-21       Impact factor: 6.200

6.  Dopamine D2 occupancy as a biomarker for antipsychotics: quantifying the relationship with efficacy and extrapyramidal symptoms.

Authors:  Rik de Greef; Alan Maloney; Per Olsson-Gisleskog; Joep Schoemaker; John Panagides
Journal:  AAPS J       Date:  2010-12-24       Impact factor: 4.009

Review 7.  Pharmacological and nonpharmacological management of delirium in critically ill patients.

Authors:  Dustin M Hipp; E Wesley Ely
Journal:  Neurotherapeutics       Date:  2012-01       Impact factor: 7.620

Review 8.  TAK-063, a novel PDE10A inhibitor with balanced activation of direct and indirect pathways, provides a unique opportunity for the treatment of schizophrenia.

Authors:  Kazunori Suzuki; Haruhide Kimura
Journal:  CNS Neurosci Ther       Date:  2018-01-09       Impact factor: 5.243

9.  Olanzapine vs haloperidol: treating delirium in a critical care setting.

Authors:  Yoanna K Skrobik; Nicolas Bergeron; Marc Dumont; Stewart B Gottfried
Journal:  Intensive Care Med       Date:  2003-12-19       Impact factor: 17.440

10.  Occupancy of dopamine D2 receptors by the atypical antipsychotic drugs risperidone and olanzapine: theoretical implications.

Authors:  W G Frankle; R Gil; E Hackett; O Mawlawi; Y Zea-Ponce; Z Zhu; L D Kochan; C Cangiano; M Slifstein; J M Gorman; M Laruelle; A Abi-Dargham
Journal:  Psychopharmacology (Berl)       Date:  2004-10       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.